The morbidity following treatment of incidental intracranial meningioma is not negligible. Considering most operated tumors are WHO grade I, treatment should be reserved for those manifesting symptoms or demonstrating substantial growth on radiological surveillance 1).
1)
Islim AI, Mohan M, Moon RDC, Rathi N, Kolamunnage-Dona R, Crofton A, Haylock
BJ, Mills SJ, Brodbelt AR, Jenkinson MD. Treatment outcomes of incidental
intracranial meningiomas: Results from the IMPACT cohort. World Neurosurg. 2020
Mar 18. pii: S1878-8750(20)30529-5. doi: 10.1016/j.wneu.2020.03.060. [Epub ahead
of print] PubMed PMID: 32200011.